Research Article

Does Acupuncture Improve Quality of Life for Patients with Pain Associated with the Spine? A Systematic Review

Shao-chen Lu, Zhen Zheng, and Charlie Changli Xue

Traditional & Complementary Medicine Research Program, Health Innovations Research Institute and Discipline of Chinese Medicine, School of Health Sciences, RMIT University, Bundoora, VIC 3083, Australia

Correspondence should be addressed to Zhen Zheng, zhen.zheng@rmit.edu.au

Received 4 November 2009; Revised 2 February 2010; Accepted 1 July 2010

Copyright © 2011 Shao-chen Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This paper aimed to evaluate the effectiveness of acupuncture for qualities of life (QoL) in patients suffering from pain associated with the spine (PAWS). Acupuncture has been shown to reduce pain severity, but its effect on QoL is unknown. PubMed, CINAHL, and Cochrane Central Register of Controlled Trials as well as EMBASE were searched. Published randomized controlled trials on PAWS comparing acupuncture with waiting-list or sham interventions were considered. Eight out of 186 trials were included. For physical functioning, acupuncture was better than waiting-list at immediate and short-term followups; and was better than sham interventions at immediate assessment (SMD = 0.40. 95% CI 0.06 to 0.74). For mental functioning, acupuncture was better than waiting-list at short-term followup (SMD = 0.27. 95% CI 0.03 to 0.51). A similar effect was observed on pain reduction. Discrepancies in point selection for relieving anxiety and insufficient training of trial acupuncturists were also identified. Acupuncture has a moderate effect on the improvement of physical functioning and pain for PAWS patients in the short term; but the effect for mental functioning is small and delayed. Future trials should address point selection and consistency in the qualifications of trial acupuncturists.

1. Introduction

Pain associated with the spine (PAWS) is defined as pain along the spine, pain on both sides of the spine, and discogenic sciatica [1]. Epidemiological data show a high correlation between neck and low back pain [2] and these pains can be considered as one condition. PAWS has a life-time prevalence of between 54% to 80% [3] and considerably impacts on patients' quality of life (QoL), including sleep [4], mood [4], psychological well-being [1], and functional ability [5]. Assessing QoL represents three of the six core domains in the IMMPACT (initiative on methods, measurement, and pain assessment in clinical trials) recommendations [6].

QoL consists of physical, mental, social and role functioning components [7]. Trials have suggested that pain and QoL are strongly related [8]. Existing systematic reviews (SRs) of acupuncture for neck or low back pain (LBP) have focused on pain, function, or disabilities assessment [9, 10] but assessment of other aspects of QoL, such as mental and social functioning, is lacking. Acupuncture is a holistic therapy as it deals with the main symptoms and the general wellbeing of the patients concurrently. There is evidence that acupuncture improves disability and function [11–13] as well as mental functioning [14–16].

The present paper evaluates the effectiveness of acupuncture on QoL and pain for patients with PAWS. The specific aims of the paper are to assess (1) both the physical and mental effects of acupuncture on PAWS when compared with waiting-list or sham intervention (SI); (2) the correlation between reduction of pain and improvement in QoL when practicable. The physical functioning consists of physical ability, disability, working status, and daily activity functioning of the patients. The mental functioning consists of mental ability, spirituality, and emotion.

2. Methods

2.1. Inclusion and Exclusion Criteria. Only randomised controlled trials (RCTs) were included. All patients with PAWS Trials must have used acupuncture involving skin penetrations in the treatment group. Acupuncture was defined as "needle insertion on the body, including the use of the filiform needle, electroacupuncture, warming needle (needling with moxibustion on top of the needles), three edge needle, dermal needle (tapping with the so-called seven-star needle or plum blossom needle), and intradermal needle" [17]. The control groups were waiting-list or SI. SI included sham acupuncture, sham TENS, and sham laser treatment.

To be included, the trial must have satisfied three criteria: (1) have included at least one QoL measure, using a validated questionnaire, such as Short Form 36 Health Survey Questionnaire (SF-36), General Health Questionnaire, Roland Morris Questionnaire (RMQ), European Quality of Life, Nottingham Health Profile, Hospital Anxiety Depression Scale, Pain Disability Index, Northwick Park Neck Pain Questionnaire, Oswestry Disability Index, Neck Disability Index, Neck Pain and Disability Index, or Japanese Orthopaedic Association Assessment; (2) have used the visual analogue scale (VAS) for pain assessment. Using the VAS rather than other pain measurements was to simplify the pain assessment; and (3) received a score of at least three on the Jadad scale [18].

The durations of the followup period [9] were defined as

- (i) immediate followup: up to seven days after the last treatment;
- (ii) short-term followup: between seven days and three months after the last treatment;
- (iii) intermediate-term followup: between three months and one year after the last treatment;
- (iv) long-term followup: more than one year after the last treatment.

2.2. Search Strategy for Identification of Trials. The following databases were searched from their inception to October 24, 2008: PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL) (via EBSCO) and the Cochrane Central Register of Controlled Trials. EMBASE (via Science Direct) was searched from its inception to October 11, 2006. Search terms and subject headings included randomised controlled trials, controlled trials, neck pain, back pain, low back pain, ankylosing spondylosis, disc protrusion, acupuncture, and acupressure were used and adapted for different databases as necessary. References lists from the included trials were searched to find other potential papers.

Languages of publication were limited to English, German, and Chinese. Authors of the trials were contacted if more information was needed.

One author (LS) conducted citation identification and trial selection. The procedure was double checked by another author (ZZ).

2.3. *Methodological Assessment*. The reporting quality of the trials was assessed with modified Jadad Scale [18] by one author (LS) and double checked by TS. Any disagreement was resolved by discussion with another author (ZZ).

2.4. Data Extraction. One author (LS) extracted data for demographics, treatment procedure, outcomes (Table 1) and items of Standards for Reporting Interventions in Controlled Trials of Acupuncture (STRICTA) [27], and data were double checked by TS. For trials reporting more than one QoL assessment, the assessment measuring the broader aspects of QoL was chosen for meta-analysis. For instance, when a trial reported both the Neck Disability Index and SF-36 physical functioning, only the SF-36 data were used. When trials only reported the combined value of SF-36), the data were not included in the meta-analysis.

2.5. Data Analysis. The results of trials with similar control interventions and duration of followup were pooled together. Data were analysed using RevMan 4.3. Randomeffects model (REM), standard mean difference (SMD), and 95% confidence interval (95% CI) were used for outcomes reported in a continuous data format. SMD was used because different measures were frequently used and REM was used to incorporate heterogeneity among the trials. Relative risk and 95% CI were used for outcomes reported in dichotomous data format. The effect size was categorised as small, medium, and large if it was equal or more than 0.20, 0.50, and 0.80, respectively [28].

2.6. Sensitivity Analysis [29]. When sufficient data were available, trials were grouped into (1) neck pain (NP), (2) LBP, and (3) other spinal pain including thoracic sacral and coccygeal pain, in order to explore the heterogeneity if there was any. Otherwise, the statistical method was changed from REM to fixed effect model (FEM) to see if there was any change in the results.

3. Results

3.1. Description of Trials. Of the 1,090 citations found and screened, 186 clinical trials were identified. Only eight trials met the selection criteria [19–26]. The main reason for exclusion was not having any QoL data or the types of outcome assessment were unclear. The selection process is illustrated in Figure 1.

Table 1 provides details of the demographic data. Overall, all included trials appropriately randomised participants. Three trials did not blind participants from the type of interventions, of which one compared acupuncture with waiting-list [26] and two [22, 24] compared acupuncture with sham TENS. Acupuncturists were not blinded in any of the trials. Assessors were blinded in five trials [20–24] and assessor blinding was not reported in three trials [19, 25, 26]. One trial had a very large number of participants (n = 2841) [26], while the other trials had 26 to 301 participants. Three trials were multicentre studies [19, 20, 26], four were single

Study	Randomisation method	Blinding	Sample size/dropout rate	Age (yr)	M/F	Multicentred trial? Acupunctur- ist versus participants	Time injury	Types of condition	Inclusion criteria	Outcome measure/followup/methods
Brinkhaus et al. [19]	. Central	WN	301/19	40–75	96:202	Yes, 45 : 301	>6 mths	LBP	VAS> 40 out of 100 mm for 7 days before tx, only used NSAID in 4 wks before tx.	 (i) A modified pain questionnaire (ii) pain disability index PDI (German) (German) (German) (ii) emotional aspects of pain (Schmerzempfindungsskala) (iv) depression scale (Allgemeine Depressionsskala) (v) SF-36 (German) (vi) Number of days with pain and taking pain medication /Followup for 52 wks/NM
Irnich et al. [20]	computer	AB	177/12	Age was not provided for the entire population. Age was only provided for each group (Acupuncture: 52.3 ± 13.3 Massage: 52.7 ± 11.5 Sham laser: 52.2 ± 13.2).	60:117	Yes, 4: 117	>1 mth	dN	Painful restriction of neck mobility, no tx for 2 wks before.	 (i) Change in the maximum pain related to motion (ii) Active ROM with a 3D ultrasound real time motion analyser (iii) VAS score of 6 cervical spine ROM (iv) pressure pain threshold bilaterally at levator scapulae, trapezius descendens, and paravertebral of C6. (v) SF-36 /3 mths/NM
Itoh et al. [21]	computer	PAB	26/5	≥65	9:17	оц	≥6 mths	LBP	Normal neurological findings of lumbosacral nerve function, leg pain permitted if less than LBP.	(i) VAS(ii) RMQ/3 wks (But the followup data were not meta-analysed due to treatment group crossed)/NM.
Kerr et al. [22]	computer	AB	60/14	41 ± 12.6	28/32	ио	>6 mths	LBP	No neurologic deficits.	 (i) SF-36 (ii) Lumbar flexion ROM (iii) Pain rating index of MPQ and VAS /6 mths/postal questionnaire

TABLE 1: Demographics and outcome assessment.

					TABLE 1: Con	ıtinued.				
Study	Randomisation method	Blinding	Sample size/dropout rate	Age (yr)	M/F	Multicentred trial? Acupunctur- ist versus participants	Time injury	Types of condition	Inclusion criteria	Outcome measure/followup/methods
Vas et al. [24]	computer	AB	123/8	≥17	22/101	оп	>3 mths	dN	Uncomplicated neck pain with motion related neck pain VAS ≥30 out of 100 mm.	(i) VAS(ii) Northwick Park Neck Pain Questionnaire(iii) SF-36 (Spanish)6 mths/NM.
Kennedy et al. [23]	computer	PAB	48/8	18–70	23/25	Unknown. 3:48	<12 wks	LBP	LBP with/without leg pain	(i) VAS(ii) RMQ(iii) a multidimensional patient-centred questionnaire /3 mths/NM
White et al. [25]	computer	PB	135/28	18–80	48/87	o N	>2 mths	NP	VAS > 30 out of 100 mm for previous 5 out of 7 pre treatment days.	 (i) VAS (ii) Neck Disability Index (iii) SF-36 (iv) Borkovec and Nau scale /52 wks/NM
Witt et al. [26]	Central	No blinding	2841/	≥18	1213/1628	Yes, 3486:11630	>6 mths	LBP	Chronic LBP	 (i) standardized questionnaires (including sociodemographic characteristics) (ii) Hannover Functional Ability Questionnaire (iii) SF-36 /6 mths/questionnaire
AB: Assessor blir. Central: Randorr computer: Randd LBP: Low back pi NP: Neck pain; RMQ: Roland Mu tx: treatment;	ded; iised by central telep mised by computer iin; MPQ: Mcd PAB: Patie prris Disability Ques VAS: Visu	hone random software Gill Pain Ques nt and assesso stionnaire; al analogue scc	uisation procedure; stionnaire; 5r blinded; ale; wk: week	Mth: month; PB: Patient blinc SF-36: Short-for WK:week.	ded; rm 36 health sur	NM: noi PDI: Pai vey;	t mentioned in Disability Ir	ndex		

4

	Immediate followup	Short-term followup	Intermediate-term followup	Long-term followup
Physical functioning	Favours acupuncture, $n = 1$	Favours acupuncture, $n = 1$	*	*
Mental functioning	No difference, $n = 1$	Favours acupuncture, $n = 1$		
Pain	Favours acupuncture, $n = 1$	Favours acupuncture, $n = 1$		

n = number of studies in this comparison.

*No data available for this comparison.

TABLE 3: A summary of meta-analysis results: acupuncture versus SI (Sham intervention).

	Immediate followup	Short-term followup	Intermediate-term followup	Long-term followup
Physical functioning	Favours acupuncture, $n = 6$	No difference, $n = 4$	Favours acupuncture, $n = 2$	*
Mental functioning	No difference, $n = 3$	No difference, $n = 1$	Favours acupuncture, $n = 2$	
Pain	Favours acupuncture, $n = 7$	Favours acupuncture, $n = 3$	No difference, $n = 3$	

n = number of studies in this comparison.

*No data available for this comparison.

centred [21, 22, 24, 25], and the remaining one trial did not provide the number of centres involved but mentioned that three acupuncturists delivered treatments [23]. The duration of pain ranged from less than 12 weeks [23] to an average of 15.8 years [19].

Five of the included trials were on LBP [19, 21–23, 26] and the remaining three were on NP [20, 24, 25]. The most frequently used measurements were VAS for pain [19–26] and SF-36 for QoL [19, 20, 22, 24–26]. The other commonly used measurements were Hannover Functional Ability Questionnaire (validated German questionnaire Funktionsfragebogen Hannover-Rucken) [19, 26], and RMQ [21, 23].

Of the six trials compared acupuncture with SI, three compared it with sham acupuncture [20, 21, 23] and the other three with sham TENS [22, 24, 25]. One of the remaining two trials compared acupuncture with waiting-list [26] and the other with both sham acupuncture and waiting-list [19]. Seven trials reported the immediate followup [19–25]; five the short-term followup [20, 21, 23, 25, 26]; and three the intermediate-term followup [19, 24, 25]. None assessed long-term followup, that is, more than one year.

The meta-analysis results are summarised in Tables 2 and 3.

3.2. Physical Functioning. Two trials compared acupuncture with waiting-list, including 2808 LBP participants [19, 26]. Acupuncture was more effective than waiting-list at the immediate (SMD = 0.68.95% CI 0.39 to 0.97) [19] and short-term followups (SMD = 0.51.95% CI 0.43 to 0.59) [26].

Figure 2(a) illustrates the results of the meta-analysis of trials comparing acupuncture with SI. Three LBP trials [19, 21, 23] and three NP trials [20, 24, 25] totalling 640 participants were included. At the immediate followup, acupuncture was more effective than SI [19–21, 23–25]. Sensitivity test was conducted but this did not change the result. To identify the source of heterogeneity, we analysed the NP trials separately from the LBP trials. The results favoured acupuncture on NP (SMD = 0.31. 95% CI 0.02 to 0.60 I² = 48%) but showed no group difference for



FIGURE 1: A flowchart of study selection.

LBP. Acupuncture was not better than SI at the short-term followup; but had a small superior effect at the intermediate-term followup.

3.3. Mental Functioning. Two trials compared acupuncture with waiting-list including 2808 LBP participants [19, 26]. One trial showed no difference between the groups [19] at the immediate followup; and the other showed a small effect favour acupuncture (SMD = 0.23.95% CI 0.15 to 0.31) [26] at the short-term followup.

One LBP [19] and two NP trials [24, 25] compared acupuncture with SI totalling 458 participants. As shown in Figure 2(b), there was no difference between the two groups at the immediate and short-term followups but a small effect favouring acupuncture was detected at the intermediate-term followup. (SMD = 0.27. 95% CI 0.03 to 0.51 $I^2 = 0\%$).

3.4. Pain. Two LBP trials compared acupuncture with waiting-list totalling 2808 participants. Acupuncture was better than waiting-list with a large to medium effect at both

TABLE 4: Detailed STRICTA information.

(a)

Study	Rationale of acupuncture	Style of acupuncture (L versus D points, APs, TPs)/types of stimulation	U versus B/number of needles used	Needle regime treatme	retention time/treatment nt (described in number of ent/period)/De Qi.
Brinkhaus et al. [19]	NM	L and D, APs, TPs/M	B/>= 10	30 min followe	/12 x/8 wks (2 x/wk for 4 wks ad by 1 x/wk for 4 wks.)/yes.
Irnich et al. [20]	TCM and other points.	L and D based on the affected meridians, APs and TPs/NM	NM/NM	30 min is elicit	/5 x/3 wks/NM, local twitch ed for TPs.
Itoh et al. [21]	TP theory	TP/NM	NM/2-7	10 min achieve	/NM/NM, but stated to e "local twitch response".
Kerr et al. [22]	CTs and TI	L and D/M	B/11	30 min	/6 x/6 wks/yes.
Kennedy et al. [23]	TI, CTs, and expert's opinion.	L and D/M with even technique	U or B depending on patient's pain/8 to 13	30 min	/3–12 x/4–6 wks/yes.
Vas et al. [24]	TI	L and D, APs/M	B/7 to 16	30 min 1 x/wk	/2 x/wk for 2 wks followed by for 1 wk/yes.
White et al. [25]	TI and experts consensus.	L and D/M	B when pain is B/6 on average.	20 min	/2 x/wk for 4 wks/yes
Witt et al. [26]	At the physicians' discretion.	At the physicians' discretion/At the physicians' discretion, but electroacupuncture, laser acupuncture and moxibustion were not permitted.	At the physicians' discretion/at the physicians' discretion.	At the j discreti physici	physicians' on/15 x/3 mths/at the ans' discretion.
	(b)				
Author and date	Acupoints used in	the trial	Acupuncturist's trainin	ng	Cointervention
Brinkhaus et al. [19]	BL20 to 34; BL50 t Huatuojiaji and Sh and 7; GB31, 34 ar For patients experi sensation, at least t APs and TPs could	o 54; GB30; GV3, 4, 5 and 6; niqizhuixia. SI3; BL40, 60 and 62; KI3 nd 41; LR3 and GV14 and 20. iencing local or pseudoradicular two local points were acupunctured. l be chosen individually.	>= 140 hours of traini >3 yrs experience.	ng,	NSAID.
Irnich et al. [20]	Frequently used po GB34, TE5. APs: co and levator scapula	Dint SI3, BL10, BL60, LR3, GB20, ervical. TPs in trapezius (near GB20) ae (near SI14).	4 experienced licensed medical acupuncturist training not mentione	s; d.	None (even no concomitant analgesics).
Itoh et al. [21]	TPs based on indiv	vidual patients' response.	4 yrs of training and 7 clinical experience.	yrs of	NM.
Kerr et al. [22]	BL23, BL25, GB30	, BL40, KI3, and GV4.	A chartered physiother trained in acupuncture experience not mentio	rapist e; ned.	A leaflet included standardized advice and exercise.
Kennedy et al. [23]	GV3, GV4, BL23, 2	25, 36, 37, 40, 56, 60, GB29-31, 34.	Senior experienced physiotherapists with 1 10 yr experience and w members of the Acupuncture Associati Chartered Physiothera	Staying active and routine medications.	
Vas et al. [24]	GB20, GB21, LR3, GB39, Yintang, GV AP: shenmen, necl thalamus, ear kidn	LI4, GB34, BL10, GV14, SI3, BL62, /20, SP6. <, liver, muscle relaxation, occiput, ley.	Accredited by the Beijing University of Medical Science (China) and >15 yrs clinical experience.		Auricular seeds and rescue medication (diclophenac) (if pain relief not obtained).
White et al. [25]	Unable to locate th	ne list of points.	Trained with the Assoc of Chartered Physiotherapists and 7 clinical experience.	vrs	Acetaminophen.
Witt et al. [26]	At physician's disc	retion.	At least >= 140 hours training and wide vari- trainings in style and acupuncture technique	of ation e.	Conventional treatments.

AP: Auricular point; B: Bilateral; CT: controlled trials; D: Distal; L: Local. LBP: Low back pain; M: Manual; Mth: month; NM: not mentioned.

TI: Textbooks information; TP: Trigger point; U: Unilateral. Wk: week; TCM: traditional Chinese Medicine; yr: year.

Evidence-Based Complementary and Alternative Medicine

Study or subcategory	Ν	Acupuncture mean (SD)	N	Sham intervention Mean (SD)	SMD (random) 95% CI	Weight (%)	SMD (random) 95% CI
01 Immediate follow-up (up to within	n 1 wee	k after last treatment	session	n)			
Irnich-SF36 RP S	52	8.06 (31.90)	58	0.00 (23.60)	-8-	18.92	0.29[-0.09, 0.66]
White-SF36 PCS	64	41.19 (7.89)	61	40.58 (9.79)	-6-	19.60	0.07 [-0.28, 0.42]
Brinkhaus-SE36 PH	140	40.5 (9.70)	70	36.20(10.30)	La.	21.21	$0.43 [0.14 \ 0.72]$
Itab 2006	12	22(150)	11	9 60 (2 10)		6 90	2.16[1.12, 2.21]
No. 2006 6F26 DCC	15	-3.3(1.30)	(2)	-8.00(3.10)		- 0.00	2.10 [1.12, 3.21]
Vas 2006 SF36 PCS	61	6.3 (11.10)	62	0.70(8.20)	-8-	19.33	0.57 [0.21, 0.93]
Kennedy 2008	24	6 (4.90)	24	7.00 (6.37)		14.15	-0.17 [-0.74, 0.39]
Subtotal (95% CI)	354		286		•	100.00	0.40 [0.06, 0.74]
Test for heterogeneity: $\chi^2 = 19.16$, <i>dj</i> Test for overall effect: $Z = 1.75$ ($P =$	f = 5 (P = 0.08)	$I = .002), I^2 = 73.9\%$					
02 Short-term follow-up (up to 3 mo	onths af	ter last treatment sess	sion)				
Irnich-SF36 RP S	49	0.83 (41.30)	57	5.83 (34.50)	4	30.91	-0.13[-0.51, 0.25]
White-SF36 PCS	59	42.49 (9.75)	59	43.75 (10.04)		31.83	-0.13 [-0.49, 0.23]
Itoh 2006	12	6.40 (4.10)	9	8.60 (3.30)		14.16	-0.56[-1.44, 0.33]
Kennedy 2008	24	5.00(4.90)	24	7 70 (7 35)		23.10	-0.43[-1.00, 0.15]
Subtotal (95% CI)	144	5.00 (1.90)	1/9	///0 (/.55)		100.00	
The for beta consistence $x^2 = 1.50$ df	_ 2 (D .	$-68)$ $t^2 - 004$	147			100.00	0.21 [0.44, 0.02]
Test for heterogeneity: $\chi^2 = 1.50, a_j$	= 5 (P)	$= .08), I^{-} = 0\%$					
Test for overall effect: $Z = 1.75 (P =$.08)						
03 Intermediate-term follow-up (bet	ween th	ree months to one ye	ear after	the last treatment	session)		
Brinkhaus-SF36 PH	137	38.91 (10.00)	68	36.10 (10.30)		54.75	0.28 [-0.01, 0.57]
Vas 2006 SF36 PCS	45	9.30 (11.00)	40	5.30 (8.00)		45.25	0.41 [-0.02, 0.84]
Subtotal (95% CI)	182		108			100.00	0.32 [0.08, 0.56]
Test for heterogeneity: $\chi^2 = 0.24$, df	= 1 (P = 1)	$= .62), I^2 = 0\%$	100		•	100.00	
Test for overall effect: $Z = 2.58 (P =$	010)	,.					
101 over all check, Z = 2.50 (1 - 1)	.010)						
04 Long-term follow-up (more than	1 year a	fter the last treatmen	t sessio	n)			
Subtotal (95% CI)	0		0				Not estimable
$T_{1} \leftarrow f_{1} = 1$, $f_{1} \leftarrow f_{2} = 1$, $f_{2} \leftarrow f_{2} \to 1$, $f_{2} \to$							
Test for heterogeneity: not applicable	2						
Test for heterogeneity: not applicable Test for overall effect: not applicable	2			I		I	
Test for heterogeneity: not applicable Test for overall effect: not applicable	2				-2 0 2	4	
Test for heterogeneity: not applicable Test for overall effect: not applicable	2			–4 – Favours sham ii	-2 0 2 nterve Favours	4 acupunctu	re
Test for heterogeneity: not applicable	2			-4 - Favours sham in	-2 0 2 nterve Favours	4 acupunctu	re
Test for heterogeneity: not applicable	2			 -4 - Favours sham in (a)	-2 0 2 nterve Favours	4 acupunctu	re
Test for heterogeneity: not applicable Test for overall effect: not applicable Study	2	Acupuncture		 -4 - Favours sham in (a) Sham intervention	-2 0 2 nterve Favours SMD (random)	4 acupunctu Weight	re SMD (random)
Test for heterogeneity: not applicable Test for overall effect: not applicable Study or subcategory	e N	Acupuncture mean (SD)	N	 -4 - Favours sham in (a) Sham intervention Mean (SD)	-2 0 2 nterve Favours SMD (random) 95% CI	4 acupunctu Weight (%)	re SMD (random) 95% CI
Test for heterogeneity: not applicable Test for overall effect: not applicable Study or subcategory 01 Immediate follow-up (up to with	N n 1 wee	Acupuncture mean (SD) k after last treatment	N session	 -4 - Favours sham in (a) Sham intervention Mean (SD)	-2 0 2 nterve Favours SMD (random) 95% CI	4 acupunctu Weight (%)	re SMD (random) 95% CI
Test for heterogeneity: not applicable Test for overall effect: not applicable Study or subcategory 01 Immediate follow-up (up to withi White-SE36 MCS	N n 1 wee 64	Acupuncture mean (SD) k after last treatment 61.07 (8.77)	N session 61	-4 - Favours sham in (a) Sham intervention Mean (SD) h) 61.56 (9.05)	-2 0 2 nterve Favours SMD (random) 95% CI	4 acupunctu Weight (%) 28.74	re SMD (random) 95% CI -0.05 [-0.41, 0.30]
Test for heterogeneity: not applicable Test for overall effect: not applicable or subcategory 01 Immediate follow-up (up to within White-SF36 MCS Brinkhaue-SF36 MH	N n 1 wee 64	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50 60 (9 50)	N session 61 70	 -4 - Favours sham in (a) Sham intervention Mean (SD) h) 61.56 (9.05) 51.00 (9.80)	-2 0 2 nterve Favours SMD (random) 95% CI	 4 acupunctu Weight (%) 28.74 42.95	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25]
Test for heterogeneity: not applicable Test for overall effect: not applicable Study or subcategory 01 Immediate follow-up (up to withi White-SF36 MCS Brinkhaus-SF36 MH	N in 1 wee 64 140 61	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5 80 (15.40)	N session 61 70 62	-4 - Favours sham in (a) Sham intervention Mean (SD) h) 61.56 (9.05) 51.00 (9.80) 6 30 (15 00)	-2 0 2 nterve Favours SMD (random) 95% CI	 4 acupunctu Weight (%) 28.74 42.95 28.30	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32]
Test for heterogeneity: not applicable Test for overall effect: not applicable or subcategory 01 Immediate follow-up (up to withi White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtrate (05% CI)	N n 1 wee 64 140 61 265	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40)	N session 61 70 62	-4 - Favours sham in (a) Sham intervention Mean (SD) 1) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00)	-2 0 2 nterve Favours SMD (random) 95% CI	 4 acupunctu Weight (%) 28.74 42.95 28.30 100 00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15]
Test for heterogeneity: not applicable Test for overall effect: not applicable Study or subcategory 01 Immediate follow-up (up to withi White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $x^2 = 0.01$ df	N in 1 wee 64 140 61 265 = 2 (P.	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = 1 00) $I^2 = 0\%$	N 5 session 61 70 62 193	-4 - Favours sham in (a) Sham intervention Mean (SD) 1) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00)	-2 0 2 nterve Favours SMD (random) 95% CI	 4 acupunctu (%) 28.74 42.95 28.30 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15]
Test for heterogeneity: not applicable Test for overall effect: not applicable Study or subcategory 01 Immediate follow-up (up to withi White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df	$\frac{N}{140}$ N = 2 (P =	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = 1.00), I ² = 0%	N 5 session 61 70 62 193	-4 - Favours sham in (a) Sham intervention Mean (SD) h) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00)	-2 0 2 nterve Favours SMD (random) 95% CI	 4 acupunctu (%) 28.74 42.95 28.30 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15]
Test for heterogeneity: not applicable Test for overall effect: not applicable Study or subcategory 01 Immediate follow-up (up to withing White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 0.01$)	$\frac{N}{140}$ $\frac{1}{61}$ $\frac{265}{2(P)}$ $\frac{2}{660}$	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = 1.00 , $I^2 = 0\%$	N session 61 70 62 193	-4 - Favours sham in (a) Sham intervention Mean (SD) n) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00)	SMD (random) 95% CI	 4 acupunctu (%) 28.74 42.95 28.30 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15]
Test for heterogeneity: not applicable Test for overall effect: not applicable Study or subcategory 01 Immediate follow-up (up to withing White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 02$ Short-term follow-up (up to 3 model)	$\frac{N}{140}$ $\frac{64}{61}$ $\frac{265}{2} = 2 (P = .66)$ on the safe	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = 1.00), $I^2 = 0\%$ ter last treatment sess	N session 61 70 62 193 sion)	-4 - Favours sham in (a) Sham intervention Mean (SD) n) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00)	SMD (random) 95% CI	 4 acupunctu Weight (%) 28.74 42.95 28.30 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15]
Test for heterogeneity: not applicable Test for overall effect: not applicable Study or subcategory 01 Immediate follow-up (up to withing White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, <i>df</i> Test for overall effect: $Z = 0.45$ ($P = 0.2$ Short-term follow-up (up to 3 model) White-SF36 MCS	N in 1 wee 64 140 61 265 = 2 (P .66) onths af 59	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = 1.00), $I^2 = 0\%$ ter last treatment sess 52.49 (8.59)	N 5 session 61 70 62 193 sion) 59	 Favours sham in (a) Sham intervention Mean (SD) 1) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00) 50.33 (10.13)	SMD (random) 95% CI	 4 acupunctu Weight (%) 28.74 42.95 28.30 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59]
Test for heterogeneity: not applicable Test for overall effect: not applicable Study or subcategory 01 Immediate follow-up (up to withing White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P =$ 02 Short-term follow-up (up to 3 model) White-SF36 MCS Subtotal (95% CI)	N in 1 wee 64 140 61 265 = 2 (P 	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = 1.00), $I^2 = 0\%$ ter last treatment sess 52.49 (8.59)	N 5 session 61 70 62 193 sion) 59 59	 Favours sham in (a) Sham intervention Mean (SD) 1) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00) 50.33 (10.13)	SMD (random) 95% CI	 4 acupunctu Weight (%) 28.74 42.95 28.30 100.00 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59]
Test for heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable or subcategory 01 Immediate follow-up (up to withing White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 02$ Short-term follow-up (up to 3 mod White-SF36 MCS Subtotal (95% CI) Test for heterogeneity: not applicable	$\frac{N}{140}$ 61 265 = 2 (P .66) onths af 59 59	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = 1.00), $I^2 = 0\%$ ter last treatment sess 52.49 (8.59)	N 5 session 61 70 62 193 sion) 59 59	 Favours sham in (a) Sham intervention Mean (SD) 1) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00) 50.33 (10.13)	SMD (random) 95% CI	 4 acupunctu Weight (%) 28.74 42.95 28.30 100.00 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59]
Test for heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable or subcategory 01 Immediate follow-up (up to withing White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 02$ Short-term follow-up (up to 3 mod White-SF36 MCS Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: $Z = 1.24$ ($P = 0.01$)	$\frac{N}{140}$ $\frac{64}{140}$ $\frac{140}{61}$ $\frac{265}{2} = 2 (P = -66)$ $\frac{59}{59}$ $\frac{59}{59}$	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = 1.00), $I^2 = 0\%$ ter last treatment sess 52.49 (8.59)	N 5 session 61 70 62 193 sion) 59 59	 Favours sham in (a) Sham intervention Mean (SD) 1) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00) 50.33 (10.13)	Anterve Favours	 4 acupunctu Weight (%) 28.74 42.95 28.30 100.00 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59]
Test for heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable or subcategory 01 Immediate follow-up (up to withing White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 02$ Short-term follow-up (up to 3 mod White-SF36 MCS Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: $Z = 1.24$ ($P = 03$ Intermediate-term follow-up (bet	$\frac{N}{64}$ 140 61 265 = 2 (P .66) 0nths af 59 59 .22) ween th	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = 1.00), $I^2 = 0\%$ ter last treatment sess 52.49 (8.59)	N 5 session 61 70 62 193 59 59 59 59 59	-4 - Favours sham in (a) Sham intervention Mean (SD) 1) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00) 50.33 (10.13) t the last treatment	session)	 4 acupunctu Weight (%) 28.74 42.95 28.30 100.00 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59]
Test for heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable or subcategory 01 Immediate follow-up (up to withing White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 02$ Short-term follow-up (up to 3 model) White-SF36 MCS Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: $Z = 1.24$ ($P = 03$ Intermediate-term follow-up (bet Brinkhaus-SF36 MH	$\frac{N}{64}$ 140 61 265 = 2 (P) 59 59 2.22) ween th 137	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = $1.00), I^2 = 0\%$ ter last treatment sess 52.49 (8.59) aree months to one ye 50.50 (10.40)	N 5 session 61 70 62 193 59 59 59 59 207 afte: 68	-4 - Favours sham in (a) Sham intervention Mean (SD) 1) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00) 50.33 (10.13) 50.33 (10.13)	session)	 4 acupunctu (%) 28.74 42.95 28.30 100.00 100.00 100.00 68.11	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59] 0.30 [0.01, 0.59]
Test for heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable or subcategory 01 Immediate follow-up (up to withing White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 02$ Short-term follow-up (up to 3 mod White-SF36 MCS Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: $Z = 1.24$ ($P = 03$ Intermediate-term follow-up (bet Brinkhaus-SF36 MH Vas 2006 SF36 MCS	$\frac{N}{140}$ 61 265 = 2 (P =	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = $1.00), I^2 = 0\%$ ter last treatment sess 52.49 (8.59) uree months to one ye 50.50 (10.40) 8.00 (13.50)	N session 61 70 62 193 sion) 59 59 59 ear after 68 40	-4 - Favours sham in (a) Sham intervention Mean (SD) h) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00) 50.33 (10.13) 50.33 (10.13)	session)	 4 acupunctu (%) 28.74 42.95 28.30 100.00 100.00 100.00 68.11 31.89	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59] 0.30 [0.01, 0.59] 0.20 [-0.23, 0.63]
Test for heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable or subcategory 01 Immediate follow-up (up to withing White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 0.2$ Short-term follow-up (up to 3 mod White-SF36 MCS Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: $Z = 1.24$ ($P = 0.3$ Intermediate-term follow-up (bet Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 1.24$ ($P = 0.3$ Intermediate-term follow-up (bet Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI)	$\frac{N}{140}$ 61 265 = 2 (P =	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = $1.00), I^2 = 0\%$ ter last treatment sess 52.49 (8.59) wree months to one ye 50.50 (10.40) 8.00 (13.50)	N session 61 70 62 193 sion) 59 59 59 car after 68 40 108	-4 - Favours sham in (a) Sham intervention Mean (SD) 1) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00) 50.33 (10.13) 50.33 (10.13) : the last treatment 47.20 (11.90) 5.20 (14.10)	session)	 4 acupunctu (%) 28.74 42.95 28.30 100.00 100.00 100.00 68.11 31.89 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59] 0.30 [0.01, 0.59] 0.20 [-0.23, 0.63] 0.27 [0.03, 0.51]
Test for heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable or subcategory 01 Immediate follow-up (up to withing White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 02$ Short-term follow-up (up to 3 mod White-SF36 MCS Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: $Z = 1.24$ ($P = 03$ Intermediate-term follow-up (bet Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.14$, df	$\frac{N}{140}$ n 1 wee 64 140 61 265 = 2 (P = .66) onths af 59 59 2.22) ween th 137 45 182 = 1 (P = .02)	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = $1.00), I^2 = 0\%$ ter last treatment sess 52.49 (8.59) mere months to one ye 50.50 (10.40) 8.00 (13.50) = $.71), I^2 = 0\%$	N session 61 70 62 193 sion) 59 59 59 car after 68 40 108	-4 - Favours sham in (a) Sham intervention Mean (SD) 1) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00) 50.33 (10.13) 50.33 (10.13) • the last treatment 47.20 (11.90) 5.20 (14.10)	SMD (random) 95% CI	 4 acupunctu (%) 28.74 42.95 28.30 100.00 100.00 100.00 68.11 31.89 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59] 0.20 [-0.23, 0.63] 0.27 [0.03, 0.51]
Test for heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable OI Immediate follow-up (up to within White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 02$ Short-term follow-up (up to 3 mod White-SF36 MCS Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: $Z = 1.24$ ($P = 03$ Intermediate-term follow-up (bet Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.14$, df Test for overall effect: $Z = 2.19$ ($P = 0.14$, df Test for overall effect: $Z = 2.19$ ($P = 0.14$) Test for overall effect: $Z = 2.19$ ($P = 0.14$)	$\frac{N}{140}$ n 1 wee 64 140 61 265 = 2 (P = .66) onths af 59 59 2. .22) ween th 137 45 182 = 1 (P = .03)	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = $1.00), I^2 = 0\%$ ter last treatment sess 52.49 (8.59) tree months to one ye 50.50 (10.40) 8.00 (13.50) = $.71), I^2 = 0\%$	N session 61 70 62 193 sion) 59 59 59 car afte: 68 40 108	-4 - Favours sham in (a) Sham intervention Mean (SD) 1) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00) 50.33 (10.13) 50.33 (10.13) • the last treatment 47.20 (11.90) 5.20 (14.10)	session)	 4 acupunctu (%) 28.74 42.95 28.30 100.00 100.00 100.00 68.11 31.89 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59] 0.20 [-0.23, 0.63] 0.27 [0.03, 0.51]
Test for heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable OI Immediate follow-up (up to within White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 02$ Short-term follow-up (up to 3 mod White-SF36 MCS Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: $Z = 1.24$ ($P = 03$ Intermediate-term follow-up (bet Brinkhaus-SF36 ME Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.14$, df Test for overall effect: $Z = 2.19$ ($P = 04$ Long-term follow-up (more than Z = 0.14, df	$\frac{N}{140}$ n 1 wee 64 140 61 265 = 2 (P =	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = $1.00), I^2 = 0\%$ ter last treatment sess 52.49 (8.59) mere months to one ye 50.50 (10.40) 8.00 (13.50) = $.71), I^2 = 0\%$ fter the last treatment	N session 61 70 62 193 sion) 59 59 59 car after 68 40 108 tt session	 Favours sham in (a) Sham intervention Mean (SD) n) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00) 50.33 (10.13) 50.33 (10.13) ∴ the last treatment 47.20 (11.90) 5.20 (14.10)	session)	 4 acupunctu (%) 28.74 42.95 28.30 100.00 100.00 100.00 68.11 31.89 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59] 0.30 [0.01, 0.59] 0.20 [-0.23, 0.63] 0.27 [0.03, 0.51]
Test for heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable OI Immediate follow-up (up to within White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 02$ Short-term follow-up (up to 3 mod White-SF36 MCS Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: $Z = 1.24$ ($P = 03$ Intermediate-term follow-up (bet Brinkhaus-SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.14$, df Test for overall effect: $Z = 2.19$ ($P = 04$ Long-term follow-up (more than Subtotal (95% CI)	$\frac{N}{140}$ $\frac{140}{61}$ $\frac{265}{2} = 2 (P + 60)$ $\frac{265}{59} = 1 (P + 60)$ $\frac{45}{182} = 1 (P + 60)$ $\frac{1}{182} = 1 (P + 16)$ $\frac{1}{182} = 1 (P + 16)$ $\frac{1}{182} = 1 $	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = $1.00), I^2 = 0\%$ ter last treatment sess 52.49 (8.59) rece months to one ye 50.50 (10.40) 8.00 (13.50) = $.71), I^2 = 0\%$ fter the last treatment	N session 61 70 62 193 59 59 59 59 59 59 59 59 59 59	-4 - Favours sham in (a) Sham intervention Mean (SD) 1) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00) 50.33 (10.13) 50.33 (10.13) • the last treatment 47.20 (11.90) 5.20 (14.10)	session)	 4 acupunctu Weight (%) 28.74 42.95 28.30 100.00 100.00 100.00 68.11 31.89 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59] 0.30 [0.01, 0.59] 0.20 [-0.23, 0.63] 0.27 [0.03, 0.51] Not estimable
Test for heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable OI Immediate follow-up (up to within White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 02$ Short-term follow-up (up to 3 mod White-SF36 MCS Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: $Z = 1.24$ ($P = 03$ Intermediate-term follow-up (bet Brinkhaus-SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.14$, df Test for overall effect: $Z = 2.19$ ($P = 04$ Long-term follow-up (more than Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable	$\frac{N}{\text{in 1 wee}}$ $\frac{64}{64}$ $\frac{140}{61}$ $\frac{265}{2} = 2 (P + 66)$ $\frac{66}{59}$ $\frac{59}{59}$ $\frac{100}{100}$	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = $1.00), I^2 = 0\%$ ter last treatment sess 52.49 (8.59) tree months to one ye 50.50 (10.40) 8.00 (13.50) = $.71), I^2 = 0\%$ fter the last treatment	N session 61 70 62 193 sion) 59 59 59 59 car after 68 40 108 40 108 tt session 0	-4 - Favours sham in (a) (a) (bham intervention Mean (SD) (a) (b) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c	session	 4 acupunctu Weight (%) 28.74 42.95 28.30 100.00 100.00 100.00 68.11 31.89 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59] 0.20 [-0.23, 0.63] 0.27 [0.03, 0.51] Not estimable
Test for heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable OI Immediate follow-up (up to within White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 02$ Short-term follow-up (up to 3 mod White-SF36 MCS Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: $Z = 1.24$ ($P = 03$ Intermediate-term follow-up (bet Brinkhaus-SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.14$, df Test for overall effect: $Z = 2.19$ ($P = 04$ Long-term follow-up (more than Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: $Z = 2.19$ ($P = 04$ Long-term follow-up (more than Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: not applicable	$\frac{N}{\text{in 1 wee}}$ $\frac{64}{61}$ $\frac{265}{2} = 2 (P = -66)$ $\frac{59}{59}$ $\frac{59}{59}$ $\frac{59}{59}$ $\frac{52}{2}$ $\frac{11}{82} = 1 (P = -66)$ $\frac{11}{9} = 1 $	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = 1.00), $I^2 = 0\%$ ter last treatment sess 52.49 (8.59) aree months to one ye 50.50 (10.40) 8.00 (13.50) = .71), $I^2 = 0\%$ fter the last treatment	N session 61 70 62 193 sion) 59 59 59 59 car after 68 40 108 tt session 0	-4 - Favours sham in (a) Sham intervention Mean (SD) n) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00) 50.33 (10.13) 50.33 (10.13) : the last treatment 47.20 (11.90) 5.20 (14.10) n)	SMD (random) 95% CI	 4 acupunctu Weight (%) 28.74 42.95 28.30 100.00 100.00 100.00 68.11 31.89 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59] 0.20 [-0.23, 0.63] 0.27 [0.03, 0.51] Not estimable
Test for heterogeneity: not applicable Test for overall effect: not applicable Test for overall effect: not applicable Test for overall effect: not applicable White-SF36 MCS Brinkhaus-SF36 MH Vas 2006 SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.01$, df Test for overall effect: $Z = 0.45$ ($P = 02$ Short-term follow-up (up to 3 mc White-SF36 MCS Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: $Z = 1.24$ ($P = 03$ Intermediate-term follow-up (bet Brinkhaus-SF36 MCS Subtotal (95% CI) Test for heterogeneity: $\chi^2 = 0.14$, df Test for overall effect: $Z = 2.19$ ($P = 04$ Long-term follow-up (more than Subtotal (95% CI) Test for heterogeneity: not applicable Test for overall effect: not applicable	$\frac{N}{\text{in 1 wee}}$ $\frac{64}{64}$ $\frac{140}{61}$ $\frac{265}{2} = 2 (P = -66)$ $\frac{59}{59}$ $\frac{59}{59}$ $\frac{59}{59}$ $\frac{522}{45}$ $\frac{182}{182} = 1 (P = -66)$ $\frac{19}{2}$ $\frac{19}{2}$ $\frac{19}{2}$	Acupuncture mean (SD) k after last treatment 61.07 (8.77) 50.60 (9.50) 5.80 (15.40) = 1.00), $I^2 = 0\%$ ter last treatment sess 52.49 (8.59) aree months to one ye 50.50 (10.40) 8.00 (13.50) = .71), $I^2 = 0\%$ fter the last treatment	N 3 session 61 70 62 193 59 59 59 59 59 59 car after 68 40 108 108 t session 0	-4 - Favours sham in (a) Sham intervention Mean (SD) n) 61.56 (9.05) 51.00 (9.80) 6.30 (15.00) 50.33 (10.13) 50.33 (10.13) 50.33 (10.13) : the last treatment 47.20 (11.90) 5.20 (14.10) n)	SMD (random) 95% CI	 4 acupunctu Weight (%) 28.74 42.95 28.30 100.00 100.00 100.00 68.11 31.89 100.00	re SMD (random) 95% CI -0.05 [-0.41, 0.30] -0.04 [-0.33, 0.25] -0.03 [-0.39, 0.32] -0.04 [-0.23, 0.15] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59] 0.23 [-0.13, 0.59] 0.20 [-0.23, 0.63] 0.27 [0.03, 0.51] Not estimable

7

(b)

FIGURE 2: Continued.

Study		Acupuncture	9	Sham intervention	SMD (random)	Weight	SMD (random)
or subcategory	N	mean (SD)	N	Mean (SD)	95% CI	(%)	95% CI
01 Immediate follow-up (up to with	hin 1 week	k after last treatment	session)			
Irnich 2001	51	24.22 (28.05)	57	17.28 (28.11)		16.23	0.25 [-0.13, 0.62]
Kerr VAS	26	51.30 (22.40)	20	-61.70 (30.60)	-8-	13.62	0.39 [-0.20, 0.98]
White VAS	63	-20.39 (20.26)	61	-30.69 (22.00)	-8-	16.49	0.48 [0.13, 0.84]
Brinkhaus VAS 2006	140	-34.50(28.50)	70	-43.70(29.80)		17.22	0.32 [0.03, 0.61]
Itoh 2006	13	-27.30 (13.50)	11	-69.60 (10.90)		→ 6.61	3.30 [2.00, 4.60]
Vas 2006 VAS	61	42.10 (21.10)	62	14.00 (15.70)	-8-	15.97	1.50 [1.10, 1.91]
Kennedy 2008	24	-27.30 (24.00)	24	-36.30 (29.88)	-8-	13.86	0.33 [-0.24, 0.90]
Subtotal (95% CI)	378		305		•	100.00	0.75 [-0.29, 1.22]
Test for heterogeneity: $\chi^2 = 44.74$, a Test for overall effect: $Z = 3.17$ ($P =$	$df = 6 \left(P + 0.002 \right)$	$< .001), I^2 = 86.6\%$					
02 Short-term follow-up (up to 3 n	nonths afte	er last treatment sessi	ion)				
White VAS	59	-17.29 (18.96)	58	-23.19 (20.88)	-8-	41.30	0.29 [-0.07, 0.66]
Itoh 2006	12	-49.50(18.80)	9	-68.30 (11.40)		23.98	1.12 [0.18, 2.06]
Kennedy 2008	24	-26.50 (25.47)	24	-40.70 (30.37)		34.72	0.50[-0.08, 1.07]
Subtotal (95% CI)	95		91		•	100.00	0.47 [0.10, 0.84]
Test for heterogeneity: $\chi^2 = 2.65$, d	f = 2(P =	$= .27), I^2 = 24.6\%$					
Test for overall effect: $Z = 2.50 (P =$	= .01)						
03 Intermediate-term follow-up (b	etween thr	ree months to one ve	ar after	the last treatment s	session)		
White VAS	54	-20.91 (25.69)	53	-24.36 (26.68)		33.12	0.13 [-0.25, 0.51]
Brinkhaus VAS 2006	137	-39.20 (29.20)	68	-44.90 (30.40)		35.08	0.19 [-0.10, 0.48]
Vas 2006 VAS	45	-41.10 (26.90)	40	-26.80(25.90)	-8-	31.79	-0.54 [-0.97, -0.10]
Subtotal (95% CI)	236		161		•	100.00	-0.05 [-0.47, 0.37]
Test for heterogeneity: $\chi^2 = 7.97$, d	f = 2(P =	$=.02), I^2 = 74.9\%$			Ť		
Test for overall effect: $Z = 0.23 (P =$	= .82)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					
04 Long-term follow-up (more that Subtotal (95% CI)	n 1 year af 0	ter the last treatment	t session 0	n)			Not estimable
Test for heterogeneity: not applicable	le						
Test for overall effect: not applicabl	e			1			
				-4 -	2 0 2	4	
				Favours sham i	nterve Favours	acupunctu	<i>•</i> e
				i avours snalli li	incrite ravours	acapunctu	

(c)

FIGURE 2: Meta-analyses of the effects of acupuncture on QoL and Pain. (a) Acupuncture versus sham interventions for physical functioning. (b) Acupuncture versus sham interventions for mental functioning. (c) Acupuncture versus sham interventions for pain.

the immediate (SMD = 0.88.95% CI 0.58 to 1.17) [19] and short-term followups (SMD = 0.69.95% CI 0.61 to 0.77) [26].

Three NP [20, 24, 25] and four LBP trials [19, 21–23] compared acupuncture with SI including 683 participants. As shown in Figure 2(c), acupuncture was more effective than SI at the immediate and short-term followups [21, 23, 25]. No group difference was identified at the intermediate-term followup. The sensitivity test and subgroup analysis were conducted and this did neither change the result nor the heterogeneity.

Due to the small number of trials included, no correlation between QoL and pain could be determined.

3.5. STRICTA. The STRICTA data are presented in Table 4. In one trial, the trial physicians were allowed to treat participants similarly to their usual practice for 15 sessions over three months as long as they used needle acupuncture without laser therapy [26]. The paper did not clearly describe what styles of acupuncture the trial physicians used. A methodological paper could not be found for the information needed. Due to lack of details, this paper is not included in the summary that follows, so only seven out of eight trials are described.

Six trials used both local and distal points [19, 20, 22–25], with two selecting points based on traditional Chinese medicine theory [20, 24]. Three trials allowed auricular points in addition to body acupuncture [19, 20, 24]. Five trials applied manual stimulation to achieve *deqi* sensation (a distending or numb sensation at the acupuncture sites) [19, 22–25], and the remaining two mentioned "local twitch response" without specify manual or electrical stimulation [20, 21]. Needle retention was at least 20 minutes in six out of seven trials [19, 20, 22–25] and 10 minutes in one trial [21]. Acupuncture treatment was given once to twice a week for 5–12 times in five trials [19, 20, 22, 24, 25].

Four clinical trials had one acupuncturist conduct all the acupuncture treatments [21, 22, 24, 25] whereas the other four clinical trials involved three [23] to 3486 [26] trial acupuncturists. The training and experiences of acupuncturists in each trial varied. Only one trial employed Evidence-Based Complementary and Alternative Medicine

acupuncturists with at least four years of formal training [21], four trials had medical acupuncturists with at least 140 hours of training [19, 26], or physiotherapy acupuncturist with 80 hours of accredited courses [23, 25], and the remaining trials did not report the training background [20, 22, 24]. In five trials, years of practice varied from three to 15 years [19, 21, 23–25], and two did not report [20, 22].

Reporting of other aspects of STRICTA varies as shown in Table 4.

4. Discussion

This SR demonstrates that acupuncture may improve physical functioning and pain and it has a delayed, small effect on mental functioning in patients with PAWS.

Our result for pain reduction in PAWS is consistent with those of two former SRs published in 2005 and 2007, where acupuncture was found to be more effective than waiting-list and SI [9, 10]. The current paper found the effect size was between medium to large. Unfortunately, the two previously published SRs did not assess mental functioning, which is important to pain sufferers, nor analysed general QoL outcomes, such as those included in SF-36.

The present paper has the following characteristics: firstly, it updates the current state of evidence on acupuncture for PAWS by including five recently published trials [19, 21, 23, 24, 26]. One of these has a sample size of 2841 participants, which may strengthen the quality of the evidence presented in this paper [26]. Secondly, only highquality trials are included to ensure clinical relevance of findings from this paper. All trials were assessed based on the Jadad scale as part of the selection process to reduce bias due to the lack of blinding and randomisation as trials with such weaknesses are more likely to produce positive outcomes [30, 31]. Thirdly, to determine the benefit of acupuncture as a stand alone therapy, only trials comparing acupuncture with waiting-list or sham acupuncture are included. That is, trials comparing acupuncture with other intervention or assessing acupuncture as an adjunctive intervention to a standard therapy [32] were excluded.

As a result, only two [20, 25] out of the ten trials reviewed in Trinh's SR [10] and one [22] out of the 35 trials in Furlan's SR [9] met the selection criteria for this paper.

The findings of the present SR are, however, contradictory to those of a recently published SR by Madsen [33], which concluded that acupuncture analgesia was clinically irrelevant and could be due to a lack of blinding of acupuncturists or psychological factors. The difference in results might be due to: (1) the present SR only included trials that scored three or higher on the Jadad scale; (2) different endpoints were used to assess the benefits of acupuncture for pain management. Madsen focused on pain reduction only whereas this SR considered both QoL and pain; and (3) this SR aimed to evaluate acupuncture for PAWS while Madsen's review covered acupuncture studies on all pain conditions. Consequently, only one [19] out of the thirteen trials included in Madsen's SR met the inclusion criteria for this paper.



Arrow indicates improvement

FIGURE 3: A hypothetical framework of the effects of acupuncture on QoL.

Similar to SRs by Furlan and Trinh, a high level of heterogeneity was detected in the present review. The sources of heterogeneity could be the variation in the pain history, assessment using different QoL instruments, and/or the use of different acupuncture treatment regimens. Some trials required a minimum of one month of pain duration whereas other trials required more than a six-month history of pain. Because not all trials used SF-36, we extracted data from SF-36 and RMQ. We use SMD instead of Weighted Mean Difference for the data analysis to address variation in pain assessment tools.

As for acupuncture regimen, the methods of point selection varied from one trial to another. Most trials used a combination of distal and local points on the body, and three trials used additional auricular acupuncture [19, 20, 24]. The number of treatments offered also varied from five to 15. Such variations could be major sources of heterogeneity.

Inclusion of both LBP and NP in one review is unlikely to be a major source of heterogeneity. These are related conditions and have been combined in clinical trials [34, 35]. Furthermore, as shown in the analysis, separating the two types of pain did not change the overall result for pain or mental functioning but there was a significant result for physical functioning in LBP trials only.

Medications such as opioids and coxibs have been reported to improve QoL, especially symptom distress scores [36]. The adverse effects of opioids ranged from mild ones such as nausea, vomiting, drowsiness, clouding of the mind, constipation, and difficulty in urination [37], to severe ones such as respiratory depression and hypotension [37]. Long-term opioid usage is associated with dependence and addiction [38]. The adverse effects of nonsteroidal antiinflammatory drugs ranged from mild, such as gastritis [39], to serious, such as aggravation of renal failure [39] and increased risk of cardiovascular events [40]. This limited their use to short term. In contrast, the adverse effects of acupuncture are short-lasting and mild, such as tiredness and drowsiness [41], making acupuncture potentially a safer choice of treatment for improving QoL of chronic PAWS patients.

We only found a delayed, small effect supporting acupuncture as improving mental functioning at three months to one year after the end of the treatments. This is consistent with findings from both the controlled and uncontrolled trials [11, 42]. Other interview or survey studies have also reported that after acupuncture, patients reported improved emotional strength [43], became calmer [14, 44, 45], and experienced positive emotional changes [46]. Considering these findings, the point selections in trials could be improved and be more focused on the mental aspects of the treatment. In the included trials in the current SR, generally a formulated protocol or a set of points is applied to address pain; whereas in clinical practice, practitioners choose different points from one session to another to address patients' needs at that session as well as the chief complaint. Furthermore, the traditionally trained acupuncturist focuses on patients' emotional issues as well as their pain. One of the main Chinese medicine principles for treating pain is to "calm the shen (mind)" [47], which is consistent with the understanding of modern medicine that pain and anxiety/mental stress reinforce each other [48]. In acupuncture, the commonly used points for calming the mind or "shen" include HT3, 4, 5, 7, 8, PC3, 5, 6, 7, LR3, 14, GV11, 20, 24, BL14, 15, 18, 62, KI9, and the extra points Si Shen Cong ("four mind points"), An Mian ("peaceful sleep"), and Yin Tang ("hall of impression") [49]. In the current paper, four out of eight trials reported mental functioning [20, 24-26] but only GV20 and LR3 were used in two trials [20, 24]. The rest of the trials did not use any points aiming to calm the mind. This discrepancy in point selection might have explained a lack of any effect on mental functioning at immediate and short-term followups. It is interesting to note that the real acupuncture had a delayed, small effect on improving mental function. To what degree this is related to the long-term effect on the physical functioning is unknown. As shown in Figure 3, it is possible that the elements of QoL improvement depend on the point selection. Future acupuncture trials in pain need to pay special attention to point selection to address both pain and mental functioning.

The STRICTA data also indicated variation in the training and clinical experience of trial acupuncturists. The duration of training ranges from 140 hours to 4 years. Trial acupuncturists' experience ranges from no mention of experience to more than 15 years. Acupuncturists require a sufficient knowledge and skill base as well as clinical experience to enable them to provide successive acupuncture treatments of a consistent quality. Such consistency is an important aspect in the reproducibility and validity of trials. The recent CONSORT statement on nonpharmacological interventions stated that formally trained and skilled practitioners are essential for the success of non-pharmacological interventions [50]. To what degree a discrepancy in training might have impact on the trial results is unknown, and this requires further systematic investigation.

5. Conclusion

For patients with PAWS, there is moderate evidence suggesting that acupuncture may improve physical functioning and pain more effectively than those in the waiting-list or SI groups. Acupuncture may have a delayed, small effect on mental functioning. Acupuncture points used to improve mental functioning should be taken into consideration in future clinical trials for pain. A consensus needs to be reached concerning acupuncture treatment regimen and practitioners' training and clinical experience.

Acknowledgments

The authors wish to thank Dr. Soheil Torktorabi (TS) for his assistance with data collection, Dr. Brian May for proofreading this paper, and Dr. Gerard Williams for his translation of German language trials. The preparation of this paper was supported by the National Health and Medical Research Council of Australia [ID 555411].

References

- L. Manchikanti, V. Singh, S. Datta, S. P. Cohen, and J. A. Hirsch, "Comprehensive review of epidemiology, scope, and impact of spinal pain," *Pain Physician*, vol. 12, no. 4, pp. E35– E70, 2009.
- [2] L. Manchikanti, V. Singh, V. Pampati, K. S. Damron, C. D. Beyer, and R. C. Barnhill, "Is there correlation of facet joint pain in lumbar and cervical spine? An evaluation of prevalence in combined chronic low back and neck pain," *Pain Physician*, vol. 5, no. 4, pp. 365–371, 2002.
- [3] M. V. Boswell, A. M. Trescot, S. Datta et al., "Interventional techniques: evidence-based practice guidelines in the management of chronic spinal pain," *Pain Physician*, vol. 10, no. 1, pp. 7–111, 2007.
- [4] E. M. Hagen, E. Svensen, H. R. Eriksen, C. M. Ihlebæk, and H. Ursin, "Comorbid subjective health complaints in low back pain," *Spine*, vol. 31, no. 13, pp. 1491–1495, 2006.
- [5] B. Natvig, D. Bruusgaard, and W. Eriksen, "Localized low back pain and low back pain as part of widespread musculoskeletal pain: two different disorders? A cross-sectional population study," *Journal of Rehabilitation Medicine*, vol. 33, no. 1, pp. 21–25, 2001.
- [6] D. C. Turk, R. H. Dworkin, M. P. McDermott et al., "Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations," *Pain*, vol. 139, no. 3, pp. 485– 493, 2008.
- [7] A. Bowling, Measuring Health: A Review of Quality of Life Measurement Scales, Open University Press, Buckinham, UK, 1997.
- [8] M. K. Young, M. Wood, and N. Jean-Noel, "Postherpetic neuralgia in older adults: culture, quality of life, and the use of alternative/complementary therapies," *Holistic Nursing Practice*, vol. 21, no. 3, pp. 124–134, 2007.
- [9] A. D. Furlan, M. van Tulder, D. Cherkin et al., "Acupuncture and dry-needling for low back pain: an updated systematic review within the framework of the cochrane collaboration," *Spine*, vol. 30, no. 8, pp. 944–963, 2005.
- [10] K. Trinh, N. Graham, A. Gross et al., "Acupuncture for neck disorders," *Spine*, vol. 32, no. 2, pp. 236–243, 2007.

- [11] H. MacPherson, A. J. Gould, and M. Fitter, "Acupuncture for low back pain: results of a pilot study for a randomized controlled trial," *Complementary Therapies in Medicine*, vol. 7, no. 2, pp. 83–90, 1999.
- [12] C. F. Meng, D. Wang, J. Ngeow, L. Lao, M. Peterson, and S. Paget, "Acupuncture for chronic low back pain in older patients: a randomized, controlled trial," *Rheumatology*, vol. 42, no. 12, pp. 1508–1517, 2003.
- [13] P. T. Dorsher and P. M. McIntosh, "Acupuncture's effects in treating the sequelae of acute and chronic spinal cord injuries: a review of allopathic and traditional Chinese medicine literature," *Evidence-Based Complementary and Alternative Medicine.* In press.
- [14] C. M. Cassidy, "Chinese medicine users in the United States part II: preferred aspects of care," *Journal of Alternative and Complementary Medicine*, vol. 4, no. 2, pp. 189–202, 1998.
- [15] C. M. Cassidy, "Chinese medicine users in the United States. Part I: utilization, satisfaction, medical plurality," *Journal of Alternative and Complementary Medicine*, vol. 4, no. 1, pp. 17–27, 1998.
- [16] J. G. Hughes, ""When I first started going I was going in on my knees, but I came out and I was skipping": exploring rheumatoid arthritis patients' perceptions of receiving treatment with acupuncture," *Complementary Therapies in Medicine*, vol. 17, no. 5-6, pp. 269–273, 2009.
- [17] H. M. Wu, J. L. Tang, X. P. Lin et al., "Acupuncture for stroke rehabilitation," *Cochrane Database of Systematic Reviews*, vol. 3, Article ID CD004131, 2006.
- [18] D. Melchart, K. Linde, P. Fischer et al., "Acupuncture for idiopathic headache," *Cochrane Database of Systematic Reviews*, no. 1, Article ID CD001218, 2001.
- [19] B. Brinkhaus, C. M. Witt, S. Jena et al., "Acupuncture in patients with chronic low back pain: a randomized controlled trial," *Archives of Internal Medicine*, vol. 166, no. 4, pp. 450– 457, 2006.
- [20] D. Irnich, N. Behrens, H. Molzen et al., "Randomised trial of acupuncture compared with conventional massage and "sham" laser acupuncture for treatment of chronic neck pain," *British Medical Journal*, vol. 322, no. 7302, pp. 1574–1578, 2001.
- [21] K. Itoh, Y. Katsumi, S. Hirota, and H. Kitakoji, "Effects of trigger point acupuncture on chronic low back pain in elderly patients—a sham-controlled randomised trial," *Acupuncture in Medicine*, vol. 24, no. 1, pp. 5–12, 2006.
- [22] D. P. Kerr, D. M. Walsh, and D. Baxter, "Acupuncture in the management of chronic low back pain: a blinded randomized controlled trial," *Clinical Journal of Pain*, vol. 19, no. 6, pp. 364–370, 2003.
- [23] S. Kennedy, G. D. Baxter, D. P. Kerr, I. Bradbury, J. Park, and S. M. McDonough, "Acupuncture for acute non-specific low back pain: a pilot randomised non-penetrating sham controlled trial," *Complementary Therapies in Medicine*, vol. 16, no. 3, pp. 139–146, 2008.
- [24] J. Vas, E. Perea-Milla, C. Méndez et al., "Efficacy and safety of acupuncture for chronic uncomplicated neck pain: a randomised controlled study," *Pain*, vol. 126, no. 1–3, pp. 245– 255, 2006.
- [25] P. White, G. Lewith, P. Prescott, and J. Conway, "Acupuncture versus placebo for the treatment of chronic mechanical neck pain. A randomized, controlled trial," *Annals of Internal Medicine*, vol. 141, no. 12, pp. 911–919, 2004.

- [26] C. M. Witt, S. Jena, D. Selim et al., "Pragmatic randomized trial evaluating the clinical and economic effectiveness of acupuncture for chronic low back pain," *American Journal of Epidemiology*, vol. 164, no. 5, pp. 487–496, 2006.
- [27] H. MacPherson, A. White, M. Cummings, K. Jobst, K. Rose, and R. Niemtzow, "Standards for reporting interventions in controlled trials of acupuncture: the STRICTA recommendations," *Complementary Therapies in Medicine*, vol. 9, no. 4, pp. 246–249, 2001.
- [28] J. Cohen, Statistical Power for the Behavioural Sciences, Academic Press, New York, NY, USA, 1977.
- [29] J. J. Deeks, J. P. T. Higgins, and D. G. Altman, "Analysing and presenting results," in *Cochrane Handbook for Systematic Reviews of Interventions Version 426*, J. Higgins, et al., Ed., The Cochrane Collaboration, 2006.
- [30] K. F. Schulz, L. Chalmers, R. J. Hayes, and D. G. Altman, "Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials," *Journal of the American Medical Association*, vol. 273, no. 5, pp. 408–412, 1995.
- [31] G. A. Colditz, J. N. Miller, and F. Mosteller, "How study design affects outcomes in comparisons of therapy. I: medical," *Statistics in Medicine*, vol. 8, no. 4, pp. 441–454, 1989.
- [32] E. Leibing, U. Leonhardt, G. Köster et al., "Acupuncture treatment of chronic low-back pain—a randomized, blinded, placebo-controlled trial with 9-month follow-up," *Pain*, vol. 96, no. 1-2, pp. 189–196, 2002.
- [33] M. V. Madsen, P. C. Gøtzsche, and A. Hróbjartsson, "Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups," *BMJ*, vol. 338, p. a3115, 2009.
- [34] L. G. F. Giles and R. Muller, "Chronic spinal pain syndromes: a clinical pilot trial comparing acupuncture, a nonsteroidal anti-inflammatory drug, and spinal manipulation," *Journal of Manipulative and Physiological Therapeutics*, vol. 22, no. 6, pp. 376–381, 1999.
- [35] Y. B. Yip, H.-M. Sonny Tse, and K. K. Wu, "An experimental study comparing the effects of combined transcutaneous acupoint electrical stimulation and electromagnetic millimeter waves for spinal pain in Hong Kong," *Complementary Therapies in Clinical Practice*, vol. 13, no. 1, pp. 4–14, 2007.
- [36] N. Katz, "The impact of pain management on quality of life," *Journal of Pain and Symptom Management*, vol. 24, no. 1, pp. S38–S47, 2002.
- [37] B. G. Katzung, *Basic and Clinical Pharmacology*, Appleton & Lange, Norwalk, Conn, USA, 2003.
- [38] B. A. Martell, P. G. O'Connor, R. D. Kerns et al., "Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction," *Annals of Internal Medicine*, vol. 146, no. 2, pp. 116–127, 2007.
- [39] D. R. Robinson, "Prostaglandins and the mechanism of action of anti-inflammatory drugs," *American Journal of Medicine*, vol. 75, no. 4 B, pp. 26–31, 1983.
- [40] G. D. Klasser and J. Epstein, "Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications," *Journal of the Canadian Dental Association*, vol. 71, no. 8, pp. 575– 580, 2005.
- [41] H. MacPherson and K. Thomas, "Short term reactions to acupuncture—a cross-sectional survey of patient reports," *Acupuncture in Medicine*, vol. 23, no. 3, pp. 112–120, 2005.
- [42] R. R. Coeytaux, J. S. Kaufman, T. J. Kaptchuk et al., "A randomized, controlled trial of acupuncture for chronic daily headache," *Headache*, vol. 45, no. 9, pp. 1113–1123, 2005.

- [43] C. Paterson and N. Britten, "Acupuncture for people with chronic illness: combining qualitative and quantitative outcome assessment," *Journal of Alternative and Complementary Medicine*, vol. 9, no. 5, pp. 671–681, 2003.
- [44] K. J. Kemper, R. Sarah, E. Silver-Highfield, E. Xiarhos, L. Barnes, and C. Berde, "On pins and needles? Pediatric pain patients' experience with acupuncture," *Pediatrics*, vol. 105, no. 4, pp. 941–947, 2000.
- [45] T. Alraek and K. Malterud, "Acupuncture for menopausal hot flashes: a qualitative study about patient experiences," *Journal* of Alternative and Complementary Medicine, vol. 15, no. 2, pp. 153–158, 2009.
- [46] A. Gould and H. MacPherson, "Patient perspectives on outcomes after treatment with acupuncture," *Journal of Alternative and Complementary Medicine*, vol. 7, no. 3, pp. 261–268, 2001.
- [47] P. Sun, *The Treatment of Pain with Chinese Herbs and Acupuncture*, Elsevier Health Sciences, 2002.
- [48] R. Melzack and P. Wall, *The Challenge of Pain*, Penguin Books, London, UK, 1996.
- [49] P. H. Li, Acupuncture Point Therapy, Chinese Medical Classical Literature, Beijing, China, 1996.
- [50] I. Boutron, D. Moher, D. G. Altman, K. F. Schulz, and P. Ravaud, "Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration," *Annals of Internal Medicine*, vol. 148, no. 4, pp. 295–309, 2008.